



## **Please Support the OPEN ACT Orphan Product Extensions Now ~ Accelerating Cures & Treatments**

Congress should incentivize the repurposing of potentially life-saving approved drugs for rare diseases and pediatric cancers. Similar incentives have been critical in the development of new medicines for underserved patient populations and could lead to hundreds of safe, effective and affordable rare disease treatments within the next five years. The OPEN ACT is sponsored in the House (H.R. 1223) by Representatives Bilirakis (R-FL) and Butterfield (D-NC). Senators Hatch (R-UT) and Klobuchar (D-MN) plan to introduce companion legislation shortly.

**Issue:** Despite advances made by the Orphan Drug Act, 95 percent of the 7,000 rare diseases still have no treatment approved by the Food and Drug Administration. Most rare disease patients are prescribed treatments off-label, at times with little clinical evidence and variable effectiveness. As a result, obtaining reimbursement for off-label treatments or procedures can be challenging for patients. Biopharmaceutical companies seldom consider repurposing approved therapies to treat rare diseases because there is little incentive for them to do so.

**Solution:** The OPEN ACT would establish a six-month marketing exclusivity extension, providing an incentive to a sponsor to repurpose an already approved therapy for a rare disease. The sponsor company would need to demonstrate that the repurposed therapy is safe and effective in treating the rare disease and obtain a rare disease indication from FDA on the drug label. The OPEN ACT is modeled on the highly successful Best Pharmaceuticals for Children Act (2002) that has led to more than 500 labeling changes for pediatric populations.

**Background:** Scientific literature shows that a single-targeted drug is likely to have multiple therapeutic uses, and that biopharmaceutical companies can repurpose drugs for the treatment of different diseases. Repurposing drugs is faster, cheaper, and presents fewer risks than traditional drug development. For complex rare diseases with small patient populations, the current economic model of drug development often lacks financial viability. Utilizing targeted, economic incentives has a proven track record of encouraging industry stakeholders to invest in the development of drugs for diseases with unmet need.

**Outcomes:** The OPEN ACT would leverage the investment already made by biopharmaceutical companies into the development of approved therapies by providing an economic incentive to explore ways to bring more treatments for rare diseases to the marketplace through the process of repurposing drugs, resulting in:

- Potentially hundreds of well-tested therapies approved and on the label for rare disease patients in the next five years.
- Major market drug prices, resulting in a reduction in the average cost of rare disease drugs.
- Fewer rare disease patients using untested and potentially ineffective drugs off-label.
- A surge in biotech investment, new jobs, and grants to research universities to conduct repurposing trials.

*To co-sponsor H.R. 1223, please contact Tom Power, office of Rep. Bilirakis (R-FL), at [thomas.power@mail.house.gov](mailto:thomas.power@mail.house.gov) or Saul Hernandez, office of Rep. Butterfield (D-NC), at [saul.hernandez@mail.house.gov](mailto:saul.hernandez@mail.house.gov). To be named as an original cosponsor on the Senate bill, please contact Stuart Portman, office of Sen. Hatch (R-UT), at [stuart.portman@hatch.senate.gov](mailto:stuart.portman@hatch.senate.gov) or Rosa Po, office of Sen. Klobuchar (D-MN) at [rosa\\_po@klobuchar.senate.gov](mailto:rosa_po@klobuchar.senate.gov).*



## 177 Supporting Patient Organizations (partial list):

Ali's Angels Foundation  
RASopathies Network USA  
International Pemphigus and Pemphigoid Foundation (IPPF)  
Autoinflammatory Alliance  
Children's PKU Network  
Global Genes Project  
GNE Myopathy International  
Gwendolyn Strong Foundation  
CureDuchenne  
EveryLife Foundation for Rare Diseases  
The Nicholas Conor Institute  
Castleman Disease Collaborative Network/Castleman's Awareness & Research Effort  
RARE Science, Inc.  
ISMRD (the International Advocate for Glycoprotein Storage Diseases)  
Supporting Our Cancer Kids  
Gold Rush Cure Foundation  
The Coalition for Pulmonary Fibrosis  
Mytonic Dystrophy Foundation  
National Fragile X Foundation  
Cure JM Foundation  
National Leiomyosarcoma Foundation  
National Organization for Rare Disorders (NORD)  
Luck2Tuck Foundation  
Desmoid Tumor Research Foundation (DTRF)  
Dravet Syndrome Foundation  
Kids v Cancer  
Genetic Alliance  
The Catherine Elizabeth Blair Memorial Foundation  
DC Outreach Inc.  
POMC Island One boy an Ocean of friends  
International FOP Association  
Gene Spotlight Inc.  
Prader-Willi Syndrome Association  
Phelan-McDermid Syndrome Foundation  
Caleb's Crusade Against Childhood Cancer  
International Waldenstrom's Macroglobulinemia Foundation (IWMF)  
Noah's Light Foundation  
A-T Children's Project  
Talia's Legacy Children's Cancer Foundation  
Joey's Wings Foundation  
Sofia's Hope, Inc.  
Bert's Big Adventure  
The Rally Foundation for Childhood Cancer Research  
Sickle Cell Warriors, Inc.  
Curing Retinal Blindness Foundation  
Noah's Hope  
Hope4Bridget Foundation  
Klippel-Feil Syndrome Freedom  
Hunter Syndrome Research Coalition  
The Children's Medical Research Foundation, Inc.  
Cure SMA  
Bear Necessities Pediatric Cancer Foundation  
Cures Within Reach  
Aiden's Army  
The MAGIC Foundation  
Center for Jewish Genetics  
Gene Giraffe Project  
The Association for Glycogen Storage Disease  
Mary Payton's Miracle Foundation  
Lymphatic Malformation Institute  
Sarcoma Foundation of America  
Team Serena  
Cure HHT  
National Tay-Sachs & Allied Diseases Association (NTSAD)  
Choroideremia Research Foundation, Inc.  
Sophia's Fund  
Amyloidosis Research Consortium  
Amyloidosis Foundation  
Relapsing Polychondritis  
Pulmonary Fibrosis Advocates  
Info and Resources for Idiopathic Pulmonary Hemosiderosis (IPH-NET)  
Fabry Support & Information Group  
PKD Foundation  
Mastocytosis Society  
Little Miss Hannah Foundation  
Let Them Be Little X2 Inc.  
CureCADASIL  
CARES Foundation, Inc.  
The Kortney Rose Foundation  
EDSers United Foundation  
The Life Raft Group  
Alexa Nawrocki Pediatric Cancer Foundation  
The Brooke Healey Foundation  
The Champ's Corner  
OsteoPETrosis Society  
Children's Cardiomyopathy Foundation  
EB Research Partnership  
Jonah's Just Begun  
Hannah's Hope Fund  
Cardio-Facio-Cutaneous International  
Hereditary Neuropathy Foundation  
Team Sanfilippo Foundation  
Sephardic Health Organization for Referral & Education  
The GIST Cancer Awareness Foundation  
The Truth 365  
The Arms Wide Open Childhood Cancer Foundation  
Pediatric Cancer Foundation  
A Kids' Brain Tumor Cure  
Hermansky-Pudlak Syndrome Network Inc.  
The Adult Polyglucosan Body Disease Research Foundation (APBDRF)  
Cooley's Anemia Foundation  
National MPS Society  
Taylor's Tale  
Cure AHC  
FMD Chat  
BRBN Alliance  
Princesses on a Mission, Inc.  
Cole vs Cancer  
The Rare Cancer Research Foundation  
Batten Disease Support & Research Association  
Fibromuscular Dysplasia Society of America (FMDSA)  
Parent Project Muscular Dystrophy  
Help Extinguish Hunter Syndrome  
Samuel Szabo Foundation  
The Global Foundation for Peroxisomal Disorders  
LMSarcoma Direct Research Foundation  
MLD Foundation  
DEFY Foundation  
Drew's Hope Scientific Research Foundation  
Dominick One in a Million  
Rare Disease United Foundation  
Cure Sanfilippo Foundation  
Chase After a Cure  
Saving Case & Friends  
Beyond Batten Disease Foundation  
The Ryan Foundation  
Bridge the Gap - SYNGAP Education and Research Foundation  
NGLY1.org  
Aware of Angels  
Abigail Alliance for Better Access to Developmental Drugs  
Angioma Alliance  
Smashing Walnuts Foundation  
Journey4ACure  
The Rare Childhood Cancer Advocacy Group  
Alex's Army Childhood Cancer Foundation